ImpediMed (ASX:IPD) signs Corporate Oncology deal with Icon Group 

Be the First to Comment Read

ImpediMed (ASX:IPD) signs Corporate Oncology deal with Icon Group 

ImpediMed (IPD), Icon Group, SOZO units, breast cancer screening, share price
Image source: © Rfischia | Megapixl.com

Highlights

  • ImpediMed has secured agreement with Icon Group to rollout 13 SOZO units. 
  • The installation of 13 SOZO units would help IPD establish lymphoedema screening services for breast cancer patients across Australia and New Zealand. 

The ASX-listed healthcare equipment company ImpediMed Limited (ASX:IPD) announced that it has signed an agreement with Icon Group to roll out 13 units of SOZO to establish lymphoedema screening services for patients who have breast cancer across Australia and New Zealand. The initial units are scheduled to be installed soon, within the coming weeks. 

About Icon group:

Icon Group is the largest specialist cancer care provider in Australia. It owns 31 cancer centres in Australia and a global presence in New Zealand, Singapore, Hong Kong and mainland China. These presence incorporate day oncology hospitals, radiation oncology facilities and comprehensive centres that bring oncology disciplines together. 

As mentioned in the Q4 FY’21 Quarterly 4C in July 2021, IPD has already started to expand its involvement with key corporate accounts. SOZO, as a digitally connected health platform. It gave ImpediMed the power to see patient testing in real-time, from any part of the world. This real-time insight enables the Company to customise its approach by better managing and reallocating resources when opportunities arise. 

About ImpediMed

ImpediMed was founded and is headquartered in Brisbane, Australia, along with operations in the US and Europe. IPD is a healthcare technology company employing progressive medical science technologies such as bioimpedance spectroscopy (BIS) technology to obtain valuable data to maximise patient health. 

Meanwhile, on the ASX, the IPD stock closed at AU$ 0.120 per share today.

Bottom line: 

Icon’s technology is capable of offering the best care to cancer patients across Australia and New Zealand. Incorporating this technology as a part of cancer treatment would surely open doors of growth opportunity for ImpediMed. 

Disclaimer

Speak your Mind

Featured Articles

Ad
kalkine logo

GET A FREE STOCK REPORT

Top Penny Picks under 20 Cents to Fit Your Pocket! Get Exclusive Report on Penny Stocks For FREE Now.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK